{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.6","value":"32.4"},{"groupId":"OG001","spread":"2.5","value":"36.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"description":"Fatigue is measured by the fatigue subscale of the Functional Assessment of Chronic Illness Therapy Questionnaire. It consists of 13 questions each answered on a 0 to 4 scale. The fatigue score is the sum of the responses with some questions reverse scored. The total Score ranges from 0 to 52, with higher scores indicating less fatigue.","dispersionType":"Standard Error","groups":[{"description":"Patients receive oral armodafinil once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity.\n\nArmodafinil: Given orally","id":"OG000","title":"Arm I - Armodafinil"},{"description":"Patients receive oral placebo once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity.\n\nplacebo: Given orally","id":"OG001","title":"Arm II - Placebo"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Participants with any data","reportingStatus":"POSTED","timeFrame":"4 weeks post-RT","title":"Fatigue","type":"SECONDARY","unitOfMeasure":"units on a scale"}